Synarel

Endometriosis, Puberty, Precocious
Treatment
4 FDA approvals
20 Active Studies for Synarel

What is Synarel

NafarelinThe Generic name of this drug
Treatment SummaryNafarelin is a hormone medication used to treat central precocious puberty and endometriosis. It works by mimicking the natural gonadotropin-releasing hormone in the body and stimulating hormones responsible for sexual development and reproductive function.
Synarelis the brand name
image of different drug pills on a surface
Synarel Overview & Background
Brand Name
Generic Name
First FDA Approval
How many FDA approvals?
Synarel
Nafarelin
1990
1

Approved as Treatment by the FDA

Nafarelin, also called Synarel, is approved by the FDA for 4 uses like Central Precocious Puberty (CPP) and Endometriosis .
Central Precocious Puberty (CPP)
Endometriosis
Endometriosis
Puberty, Precocious

Effectiveness

How Synarel Affects PatientsNafarelin is a drug that works to stimulate the pituitary gland to release hormones, LH and FSH, which in turn lead to a rise in gonadal steroid production. Taking this drug twice a day lead to decreased gonadal steroid levels after about 4 weeks. When the treatment is stopped, normal pituitary and ovarian function is restored, and the levels of estradiol return to the pre-treatment levels. It should be noted that endometriosis may return after stopping any hormonal therapy or surgery that leaves the ovaries and/or uterus intact.
How Synarel works in the bodyNafarelin works by blocking the GnRH receptor and decreasing production of hormones like estrogen and testosterone. This leads to a decrease in secondary sexual characteristics in children, a dramatic decrease in the hormones that cause endometriosis, and the suppression of growth in children. When nafarelin is stopped, hormone levels usually return to what they were before treatment.

When to interrupt dosage

The measure of Synarel is subject to the identified affliction. The amount of dosage is contingent upon the method of administration detailed in the below table.
Condition
Dosage
Administration
Endometriosis
, 2.0 mg/mL, 0.2 mg/pump actuation
Nasal, , Aerosol, metered, Aerosol, metered - Nasal, Liquid, Liquid - Nasal, Spray, metered, Spray, metered - Nasal
Puberty, Precocious
, 2.0 mg/mL, 0.2 mg/pump actuation
Nasal, , Aerosol, metered, Aerosol, metered - Nasal, Liquid, Liquid - Nasal, Spray, metered, Spray, metered - Nasal

Warnings

Synarel has two contra-indications, thus it should not be used in cases of the conditions in the following table.Synarel Contraindications
Condition
Risk Level
Notes
Pulse Frequency
Do Not Combine
Vaginal Hemorrhage
Do Not Combine
There are 20 known major drug interactions with Synarel.
Common Synarel Drug Interactions
Drug Name
Risk Level
Description
Capromab pendetide
Major
Nafarelin may decrease effectiveness of Capromab pendetide as a diagnostic agent.
Corifollitropin alfa
Major
The therapeutic efficacy of Corifollitropin alfa can be increased when used in combination with Nafarelin.
Choline C 11
Minor
Nafarelin may decrease effectiveness of Choline C 11 as a diagnostic agent.
Acipimox
Moderate
The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Nafarelin is combined with Acipimox.
Aluminium clofibrate
Moderate
The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Nafarelin is combined with Aluminium clofibrate.
Synarel Toxicity & Overdose RiskTests on animals have found no negative effects from administering up to 60 times the recommended human dose of GnRH analogs. So far, no negative effects have been reported from overdosing on this drug.
image of a doctor in a lab doing drug, clinical research

Synarel Novel Uses: Which Conditions Have a Clinical Trial Featuring Synarel?

30 active studies are presently investigating the potential of Synarel to address Central Precocious Puberty (CPP) symptoms.
Condition
Clinical Trials
Trial Phases
Puberty, Precocious
1 Actively Recruiting
Phase 3
Endometriosis
28 Actively Recruiting
Early Phase 1, Phase 2, Not Applicable, Phase 3, Phase 4

Synarel Reviews: What are patients saying about Synarel?

4.3Patient Review
2/22/2017
Synarel for Endometriosis
This is the only treatment that has given me any relief from my endometriosis. I've been using it for three months now, and it's really helped. However, under the new insurance program, I won't be able to afford it.
3Patient Review
5/15/2014
Synarel for Endometriosis
This was my doctor's go-to recommendation for endometriosis after two surgeries. It took a little while to start working, but it completely changed my life for the better. I was pain-free for three years – something I hadn't experienced since I was a preteen. Unfortunately, when my original prescribing doctor retired, their replacement refused to let me continue taking it because they said I had been on it for too long (six years). Just a few short years later, I ended up getting a complete hysterectomy. If only I could have stayed on the Synarel!
2.3Patient Review
2/19/2014
Synarel for Endometriosis
This treatment caused me severe sinus pain, and I developed ringing in my ears after using it for just two weeks. The ringing/fuzzy sound is still happening even after stopping the spray five weeks into the course.I have stopped using it and, two weeks later, I am still having trouble hearing over the noise in my ears. It did start to ease some of my abdominal pains but, overall, this was a very unpleasant experience.
1Patient Review
5/8/2010
Synarel for Endometriosis
Do not use this medication under any circumstances. It caused me debilitating, long-term depression and I will never be the same.
image of drug pills surrounding a glass of water symbolizing drug consumption

Patient Q&A Section about synarel

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Is Synarel a hormone blocker?

"Nafarelin spray interrupts the creation of regularly occurring female sexual orientations. Your PCP will reveal to you how often to utilize it. You might need to rehash the portion on the off chance that you sneeze promptly in the wake of utilizing the shower."

Answered by AI

What is Synarel used for in IVF?

"A specialist may prescribe Synarel to assist with in-vitro fertilisation (IVF) by decreasing the amount of estrogen produced by the ovaries. This provides more control for subsequent stimulation of the ovaries to produce eggs."

Answered by AI

What does Synarel spray do?

"This medication helps to decrease the amount of abnormal tissue, as well as the symptoms of endometriosis, such as pelvic pain, painful menstrual cramps, and pain during/after sex. This medication is also used by children to treat a certain type of early puberty, known as central precocious puberty, which is caused by an excess of gonadotropins."

Answered by AI

How quickly does Synarel work?

"For that reason, you need to take it as an intranasal spray two to three times a day, starting two to three months before you want your periods to stop.

Reduced oestrogen levels will usually be observed after one month of taking Synarel, in the form of either stopped or reduced periods. Synarel needs to be absorbed into the bloodstream in order to be effective, so it is administered as an intranasal spray two to three times a day, ideally starting two to three months before periods are desired to be stopped."

Answered by AI

Clinical Trials for Synarel

Image of University Hospitals Cleveland Medical Center in Cleveland, United States.

Ketamine for Pelvic Pain

18 - 89
Female
Cleveland, OH
The purpose of this research study is to see if ketamine infusion during surgery can decrease pain after surgery. Ketamine is a medication commonly used as part of anesthesia during surgery and is approved by the US FDA. Patients will be randomized to either receive standard anesthesia with OR without ketamine. The surgical procedure will be the same regardless of which group patients are randomized to. After surgery, patients will be asked to rate their pain in the post-operative observation unit and at their two-week post-operative visit. No additional visits are required for participation in this study. The investigators estimate the surveys will take approximately 10 minutes to complete.
Phase 4
Waitlist Available
University Hospitals Cleveland Medical CenterAdi Cosic, DO
Have you considered Synarel clinical trials? We made a collection of clinical trials featuring Synarel, we think they might fit your search criteria.Go to Trials
Image of Baylor College of Medicine in Hosuton, United States.

Dronabinol for Endometriosis

18 - 64
Female
Hosuton, TX
This exploratory, proof-of-concept study is a double-blind (participants and investigators will be blinded), placebo-controlled, randomized, two-arm clinical trial of Marinol \[dronabinol, synthetic Δ9-tetrahydrocannabinol (THC)\] for e endometriosis-associated chronic pelvic pain (endo-CPP) with a 2:1 allocation ratio. Up to 75 subjects will be enrolled in this pilot study and randomized to receive doses of THC (up to 30 mg/day), orally, over 8 weeks. This study will be conducted at a single site; it does not include any stratifications, and there is no interim analysis planned. Notably, the goal is to determine whether there is enough evidence of the safety of THC to support the development of later-phase clinical trials. Thus, detailed developmental plans are contingent on the outcomes of this study.
Phase 2
Waitlist Available
Baylor College of Medicine (+1 Sites)Christopher Verrico, PhD in Pharmacology
Image of Boston Children's Hospital in Boston, United States.

Metformin for Endometriosis

15 - 35
Female
Boston, MA
The goal of this pilot trial is to learn if a novel non-hormonal treatment, metformin hydrochloride, works to treat pelvic pain in young women with endometriosis. The main questions it aims to answer are: * Is metformin superior to placebo in alleviating pain symptoms in young women with endometriosis? * Does metformin alter systemic inflammatory markers over 6 months in young women with endometriosis? Researchers will compare metformin to a placebo (a look-alike substance that contains no drug) to see if metformin works to treat pelvic pain. Participants will: * Take drug metformin or a placebo every day for 6 months * Visit the clinic three times: once at baseline (pre-treatment), once at 3 months, and once at 6 months * Keep a daily symptom diary to track pain, bleeding, and usage of any pain medications
Phase 2
Recruiting
Boston Children's HospitalJessica Shim, MD
Image of WashU Medicine in Saint Louis, United States.

Peer Empowered Endometriosis Pain Support for Endometriosis

18 - 48
Female
Saint Louis, MO
The goal of this clinical trial is to determine if Peer Empowered Endometriosis Pain Support (PEEPS), an 8-week interdisciplinary, integrative group care program, decreases pain interference in participants with endometriosis-associated chronic pelvic pain between the ages 18 and 48. The main question we aim to answer is: Is PEEPS more effective than Education in decreasing pain interference? Researchers will compare people receiving PEEPS plus usual care to those receiving Education plus usual care to see if people participating in PEEPS demonstrate improvements in pain, physical function, and quality of life. Participants will: * Complete baseline quality of life surveys * Participate in an 8-session group care program * Provide feedback on each session and the program globally * Complete follow up quality of life surveys at PEEPS completion, 6- and 12-months post-completion. * A sub-set will complete semi-structured interviews or focus groups about the experience of participating in PEEPS
Recruiting
Has No Placebo
WashU Medicine (+1 Sites)Whitney Ross, MD
Have you considered Synarel clinical trials? We made a collection of clinical trials featuring Synarel, we think they might fit your search criteria.Go to Trials
Image of McGill University Health Center in Montreal, Canada.

elleFA App for Endometriosis

18+
Female
Montreal, Canada
Endometriosis is a chronic incurable disease where endometrial-like tissue grows outside of the uterus, and causes symptoms such as debilitating menstrual pain, pain during intercourse, infertility, constipation, and bloating, which hurts their quality of life. Endometriosis is estimated to affect approximately 10% of women. Despite this, there's currently not enough research on this disease; in Canada it takes on average 5.4 years to get a diagnosis (from when symptoms start), and once diagnosed, women often have to go through a trial-and-error process to find a treatment that can manage their symptoms. Misunderstanding symptoms and struggling with patient-provider communication both contribute to these delays in diagnosis and finding the best treatment. Mobile health applications have been a promising new tool to self-track symptoms and treatments. There are several apps currently available on the market for logging chronic pain, menstrual cycles, and fertility. However, no apps exist specifically for endometriosis that look at the whole spectrum of symptoms, including pain, quality of life, and especially ease of patient-provider communication. The elleFA app is a new, personal endometriosis and health tracking app designed to improve patient-physician dialogue through more direct, efficient, and impactful communication, as patients navigate their condition. This single-arm interventional study aims to test the feasibility of implementing the new elleFA app in a clinical setting for 6 months in pre-menopausal women 18 years and older with endometriosis, and the app's impact on patient experience. Participants will download the elleFA app on their smartphone and will be asked to complete two questionnaires through the app every month for 6 months. Participants can choose to also optionally track their daily symptoms, lifestyle, and treatments, through weekly symptom log summaries through the app. The main study finding will be be patient adherence to using the app over a 6 month study period. Other findings will include user-reported satisfaction with the elleFA app, and the impact of elleFA app use on patient experience communicating with their healthcare team.
Recruiting
Has No Placebo
McGill University Health CenterAndrew Zakhari, MD
Image of Main Line Health in Wynnewood, United States.

Relugolix Combination Therapy for Endometriosis

18+
Female
Wynnewood, PA
The goal of this investigator-initiated single-site clinical trial is to compare the overall quality of life of participants taking Relugolix combination therapy (Rel-CT) following excisional surgery for endometriosis to participants that do not take Rel-CT following the same surgery. Rel-CT is an FDA approved form of medical treatment for endometriosis. It is known to work in treating endometriosis pain. However, investigators do not know whether or not there is a benefit to beginning Rel-CT immediately following surgery. This study will test if patients who take Rel-CT after surgery have better quality of life and less chance the endometriosis comes back, requiring additional surgery. The main question it aims to answer is: \- Does taking Rel-CT following excisional surgery for endometriosis result in higher Endometriosis Health Profile 30 (EHP-30) scores, indicating a positive impact on overall health-related quality of life and well-being? Participants will: * Be randomly assigned to one of two treatment groups. One treatment group will take study drug Rel-CT after having excisional surgery, and the other treatment group will just have the surgery alone. * Be asked to complete questionnaires, called the Endometriosis Health Profile 30 (EHP-30) at 4 timepoints. The first time is before surgery, then at follow-up visits at 1 month, 3 months, and 6 months. The survey has 30 questions that ask about pain, control, powerlessness, emotional well-being, social support, and self-image. Researchers will compare the two treatment groups (Rel-CT and non Rel-CT) to see if there is a change in EHP-30 scores.
Phase 3
Recruiting
Main Line HealthJordan Klebanoff, MDPfizer
Image of McLean Function Measurement Lab in Ottawa, Canada.

Repetitive Transcranial Magnetic Stimulation for Endometriosis Pain

18 - 60
Female
Ottawa, Canada
The goal of this research is to improve pain outcomes for the over 500K Canadian women, girls and gender-diverse individuals who are newly diagnosed with endometriosis each year. Chronic pain that persists after interventions for endometriosis is a huge problem. There is some evidence that endometriosis-associated pain (EAP) is, at least to some extent, associated with changes in pain physiology, particularly central sensitization of pain. There is currently no effective evidence-informed intervention that addresses EAP. Yet a recent feasibility trial on a repetitive transcranial magnetic stimulation (rTMS) intervention demonstrated promising results compared to a sham intervention for reducing pain in a sample with EAP. The objectives of this trial are: 1. to evaluate the effectiveness of an rTMS intervention for pain reduction among those with recalcitrant post-operative EAP, 2. to inform on the utility of a long (10 session) vs short (5 session) protocol for pain reduction among those with recalcitrant post-operative EAP 3. to determine if any improvements in pain observed 30 days after an rTMS intervention are retained 6 months later 4. to identify physical and psychosocial mediators that impact the successful reduction of pain among patients with EAP treated using rTMS. 5. to describe patients' perceptions of and satisfaction with rTMS as an intervention for EAP.
Recruiting
No Prior Treatment
McLean Function Measurement LabLinda McLean, PhD
Have you considered Synarel clinical trials? We made a collection of clinical trials featuring Synarel, we think they might fit your search criteria.Go to Trials
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Terms of Service·Privacy Policy·Cookies·Security